Zimmer Biomet (NYSE:ZBH) Releases FY 2026 Earnings Guidance

Zimmer Biomet (NYSE:ZBH) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 8.470-8.590 for the period, compared to the consensus EPS estimate of 8.480. The company issued revenue guidance of $8.6 billion-$8.6 billion, compared to the consensus revenue estimate of $8.5 billion.

Analyst Ratings Changes

Several research firms recently weighed in on ZBH. Citigroup cut their target price on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research note on Thursday, May 28th. Zacks Research downgraded shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a report on Monday, July 27th. Weiss Ratings lowered Zimmer Biomet from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, July 20th. BMO Capital Markets began coverage on Zimmer Biomet in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $95.00 target price on the stock. Finally, UBS Group assumed coverage on Zimmer Biomet in a research note on Tuesday, July 28th. They set a “buy” rating and a $115.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, twelve have issued a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $102.00.

Zimmer Biomet Trading Up 2.1%

NYSE ZBH traded up $2.03 on Wednesday, hitting $97.84. 2,452,659 shares of the stock were exchanged, compared to its average volume of 2,312,233. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. Zimmer Biomet has a 52-week low of $79.12 and a 52-week high of $108.29. The firm has a market capitalization of $18.93 billion, a P/E ratio of 25.44, a P/E/G ratio of 2.86 and a beta of 0.45. The stock has a fifty day moving average price of $89.30 and a two-hundred day moving average price of $89.95.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.06. The business had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Research analysts forecast that Zimmer Biomet will post 8.48 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, June 25th were paid a $0.24 dividend. The ex-dividend date of this dividend was Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 24.94%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the sale, the insider owned 27,251 shares in the company, valued at $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.28% of the company’s stock.

Trending Headlines about Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q2 results exceeded expectations. Zimmer Biomet reported $2.177 billion in second-quarter sales, up 4.8% year over year and above the $2.13 billion analyst estimate. Adjusted diluted EPS was $2.07, beating consensus of $2.01. Zimmer Biomet Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Full-year guidance was raised. The company now expects 2026 adjusted EPS of $8.47 to $8.59, broadly in line with the $8.48 consensus, and revenue of approximately $8.6 billion, above the roughly $8.5 billion analyst estimate. Zimmer Biomet raises guidance on Q2 beats
• Positive Sentiment: Underlying growth remained healthy. Second-quarter sales increased 4.0% on an organic constant-currency basis, while reported diluted EPS rose 33.8% to $1.03, supporting the market’s favorable initial reaction. Zimmer Biomet Announces Second Quarter 2026 Financial Results
• Neutral Sentiment: Adjusted profitability was mixed. Adjusted EPS of $2.07 was unchanged from the prior-year period despite revenue growth, indicating that operating-cost or margin pressures offset some of the sales improvement. Analysts and investors will likely focus on the company’s margin trajectory and execution against the upgraded outlook.

Institutional Investors Weigh In On Zimmer Biomet

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Brighton Jones LLC bought a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $204,000. Sivia Capital Partners LLC bought a new stake in shares of Zimmer Biomet in the 2nd quarter valued at about $232,000. United Bank lifted its position in shares of Zimmer Biomet by 10.7% in the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after purchasing an additional 1,153 shares during the period. Federated Hermes Inc. boosted its stake in shares of Zimmer Biomet by 129.2% during the second quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock valued at $194,000 after purchasing an additional 1,202 shares in the last quarter. Finally, Cerity Partners LLC boosted its stake in shares of Zimmer Biomet by 93.6% during the second quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock valued at $7,004,000 after purchasing an additional 37,116 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.